Statement on human papillomavirus DNA test utilization§

Authors

  • Diane Solomon MD,

    Corresponding author
    1. Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland
    • Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Executive Plaza North, Room 2130, 6130 Executive Blvd., Rockville, MD 20852
    Search for more papers by this author
    • Fax: (301) 480-9939

  • Jacalyn L. Papillo CT (ASCP),

    1. Anatomic Pathology Department, Fletcher Allen Health Care, Burlington, Vermont
    Search for more papers by this author
  • Diane D. Davey MD

    1. Department of Medical Education, University of Central Florida, College of Medicine, Orlando, Florida
    Search for more papers by this author

  • This article is being published jointly in 2009 in Cancer Cytopathology (online: May 4, 2009; print: June 25), Journal of Lower Genital Tract Disease, Diagnostic Cytopathology, Acta Cytologica (print: May/June), American Journal of Clinical Pathology, and Archives of Pathology and Laboratory Medicine.

  • This is a government work and, as such, is in the public domain in the United States of America.

  • §

    In addition to the listed authors, the following individuals are also members of the Cytopathology Education and Technology Consortium and contributed to this statement: Karen Atkison, MPA, CT(ASCP), American Society of Cytopathology; Marluce Bibbo, MD, FIAC, International Academy of Cytology; George Birdsong, MD, American Society of Cytology; Tom Bonfiglio, MD; American Society for Clinical Pathology; Lydia Howell, MD, Papanicolaou Society of Cytopathology; Elizabeth Jenkins, MS, American Society of Cytopathology, administrative support; Lynnette Savaloja, SCT(ASCP), American Society for Cytotechnology; and David Wilbur, MD, College of American Pathologists.

  • See also pages 149–50.

Abstract

This statement summarizes the expanded role of human papillomavirus (HPV) testing in the screening and management of cervical cancer. It also highlights circumstances in which HPV testing is not appropriate and may lead to overtreatment.

Ancillary